Dr. Clay Siegall is a biotechnology expert with almost 30 years’ experience in this field. He worked for the National Cancer Institute and National Institutes of Health from 1988 to 1991. Between 1991 and 1997, he worked for the Bristol-Myers Squibb Pharmaceutical Research Institute. He serves on the boards of quite a number of high-profile biotechnology and pharmaceutical companies. Dr. Siegall holds a degree in Zoologyand a Ph.D. in Genetics. He has been a member of the board of directors of Ultragenyx, a biopharmaceutical company committed to developing drugs to treat rare genetic diseases, since January 2014.
Dr. Siegall was one of the founders of Seattle Genetics in 1998 and is the company’s current president and CEO. He also chairs the board of the company. He has led the company for almost 14 years now. Seattle Genetics is a biotechnology company based in Bothell, Washington, that is focused on developing a range of antibody-based therapies for the treatment of cancer and other autoimmune conditions.
In addition to their commitment to developing treatments for cancer, the company is also working on developing a diverse portfolio of products to address other medical needs. The company has grown from just about 100 employees 10 years ago to almost 1000 this year under the able leadership of Dr. Siegall. He was inspired to study cancer at a cellular level after his father died of brain cancer.
Seattle Genetics has only one commercialized drug known as Adcetris so far. The drug is now being tested in different types of cancer, especially lymphomas. The results of these tests will potentially have a great impact on the company and on the field of cancer research.
Dr. Siegall has great aspirations for the cancer research field and is determined to develop effective cancer treatments through his company with help from the other companies he works closely with.